Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer
- 16 February 2006
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 32 (3) , 180-190
- https://doi.org/10.1016/j.ctrv.2006.01.001
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic SignificanceOncology, 2005
- Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian CarcinomaInternational Journal of Gynecological Pathology, 2005
- Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinomaCancer, 2003
- Cyclooxygenase-2 (COX-2), Epidermal Growth Factor Receptor (EGFR), and Her-2/neu Expression in Ovarian CancerGynecologic Oncology, 2002
- Mechanism of action of trastuzumab and scientific updateSeminars in Oncology, 2001
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- c‐erbB‐2 anti‐sense phosphorothioate oligodeoxynucleotides inhibit growth and serum‐induced cell spreading of p185c‐erbB‐2‐overexpressing ovarian carcinoma cellsInternational Journal of Cancer, 1995
- Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancyZeitschrift für Krebsforschung und Klinische Onkologie, 1994
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987